RTOG 1122. Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab with or without AMG 386 in Patients with Recurrent Glioblastoma or Gliosarcoma
Mitchel Fromm, MD
McDowell Cancer Research at 330-344-6348
RTOG 1205. Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
Akron General Medical Center 1 Akron General Avenue (Formerly 400 Wabash Avenue) Akron, OH 44307 330-344-6000 1-800-221-4601 © 2014 Akron General Health System
This site complies with the HONcode standard for trustworthy health information: verify here.